Archive for the ‘Sorrento Therapeutics’ Category

Sorrento Therapeutics

March 16th, 2016 | Posted in 2016, Sorrento Therapeutics

San Diego’s Sorrento Therapeutics and South Korean pharmaceutical company Yuhan formed ImmuneOncia Therapeutics, a joint venture, to develop and commercialize potential anti-cancer treatments. ImmuneOncia will focus on immune checkpoint inhibitors against undisclosed targets in certain blood cancers and solid tumors.  

TNK Therapeutics, Inc.

September 4th, 2015 | Posted in 2015, Sorrento Therapeutics, TNK Therapeutics

TNK Therapeutics, Inc, a wholly owned subsidiary of Sorrento Therapeutics, has acquired the multiple preclinical and clinical stage chimeric antigen receptor immunotherapy programs, as well as underlying CAR-T technology, via the purchase of two privately-held biotech companies.

Sorrento Therapeutics

June 2nd, 2015 | Posted in 2015, Sorrento Therapeutics

Sorrento Therapeutics, San Diego, sold the rights to its proposed cancer treatment called Cunviloq to Illinois-based NantPharma in a deal worth up to $1.3 billion.

Sorrento Therapeutics Inc.

July 31st, 2014 | Posted in 2014, Sorrento Therapeutics

Sorrento Therapeutics has been awarded a Phase 1 Small Business Technology Transfer Research grant from the National Cancer Institute. The late-stage clinical oncology company develops treatments for cancer and received the grant for pre-clinical development of a small molecule inhibitor targeting the oncogenic transcription factor Myc. Abnormal Myc is believed to play a substantial role […]

Sorrento Therapeutics

December 4th, 2013 | Posted in 2013, Sorrento Therapeutics

Sorrento Therapeutics – San Diego:  Has entered into an antibody and vaccine development collaboration with The Scripps Research Institute (TSRI) of La Jolla.  Under the terms of the agreement, Sorrento Therapeutics obtains an exclusive, global license to TSRI”S novel technologies based on ghrelin signaling inhibition for the prevention and treatment of obesity and other metabolic […]